Kura Oncology adds 750,000 shares to inducement plan; total 3.25M

Kura Oncology amended its 2023 Inducement Option Plan to reserve an additional 750,000 shares of common stock, increasing the plan’s total reserve to 3,250,000 shares.

Rhea-AI Filing Summary

Kura Oncology amended its 2023 Inducement Option Plan to reserve an additional 750,000 shares of common stock, increasing the plan’s total reserve to 3,250,000 shares. These shares are designated exclusively for nonstatutory stock option grants to new hires as an inducement to join the company, consistent with Nasdaq Listing Rule 5635(c)(4). The Board approved the amendment on October 15, 2025, without stockholder approval as permitted by the rule. A complete copy of the amended plan is filed as Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did KURA change in its equity plans?

The Board approved an amendment to the 2023 Inducement Option Plan, adding 750,000 shares for new-hire nonstatutory stock options.

How many total shares are now reserved under KURA's inducement plan?

The total reserve increased to 3,250,000 shares of common stock.

Who can receive options under KURA's inducement plan?

Individuals not previously employed or directors (or after a bona fide break in service) as an inducement to employment.

Did KURA obtain stockholder approval for this amendment?

No. It was approved without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).

What type of awards does the plan cover?

It is limited to nonstatutory stock options granted as inducements to employment.

Where can I find the full terms of the amended plan?

The complete plan and related forms are provided in Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/16/2025 - 12:00 AM Learn about SEC filing dates

12730 High Bluff Drive Suite 400 San Diego CA 0001422143 false 0001422143 2025-10-15 2025-10-15 0001422143 dei:FormerAddressMember 2025-10-15 2025-10-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2025

KURA ONCOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-37620		61-1547851
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
4930 Directors Place, Suite 500, San Diego, CA				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 500-8800

12730 High Bluff Drive, Suite 400

San Diego, CA 92130

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		KURA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 15, 2025, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”), the Board approved an amendment to the Company’s 2023 Inducement Option Plan, as amended, to reserve an additional 750,000 shares of the Company’s common stock, for a new total of 3,250,000 shares of the Company’s common stock, to be used exclusively for grants of nonstatutory stock options to individuals that were not previously employees or directors of the Company (or following a bona fide period of non-employment), as an inducement material to the individual’s entry into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) (the “Amended Inducement Plan”). The Amended Inducement Plan was approved without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).

A complete copy of the Amended Inducement Plan is filed herewith as Exhibit 99.1. The above summary of the Amended Inducement Plan does not purport to be complete and is qualified in its entirety by reference to such exhibit.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Kura Oncology, Inc. 2023 Inducement Option Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Kura Oncology, Inc.
Date: October 16, 2025				By:		/s/ Teresa Bair
						Teresa Bair
						Chief Legal Officer